Earnings ·
Immuneering dosed first patient in pivotal Phase 3 trial for atebimetinib in pancreatic cancer
IMRXImmuneering Corp
Immuneering Corporation reported financial results for the quarter ended June 30, 2026. The company ended Q2 with $182.7 million in cash and marketable securities, providing an anticipated runway into 2029. Research and development expenses increased to $14.0 million from $10.5 million in the prior year period, while general and administrative expenses rose to $5.0 million from $4.3 million. The net loss attributable to common stockholders was $17.3 million, or $0.27 per share, compared to a $14.4 million loss, or $0.40 per share, in the same quarter of 2025. Operationally, Immuneering announced it has dosed the first patient in its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in combination with chemotherapy for first-line pancreatic cancer. The company also highlighted compelling Phase 2a data presented at ASCO showing a 17.3-month median overall survival and appointed Andrew Gengos as Chief Financial Officer. Immuneering Corporation is a late-stage clinical oncology company focused on developing Deep Cyclic Inhibitors to treat RAS, RAF, and MAPK-driven cancers.